Provided by Tiger Fintech (Singapore) Pte. Ltd.

ANTENGENE-B

7.780
-0.120-1.52%
Volume:4.79M
Turnover:37.84M
Market Cap:5.28B
PE:-13.83
High:8.160
Open:7.880
Low:7.610
Close:7.900
52wk High:8.160
52wk Low:0.530
Shares:679.00M
HK Float Shares:679.00M
Volume Ratio:0.75
T/O Rate:0.71%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.563
ROE:-25.98%
ROA:-13.05%
PB:6.31
PE(LYR):-13.83
PS:57.28

Loading ...

Hong Kong Stocks Movement | ANTENGENE-B (06996) Surges Over 10% in Afternoon Trading on Share Buyback Plan and ATG-022 Breakthrough Therapy Designation

Stock News
·
Sep 03

BRIEF-Antengene Corp To Repurchase Shares At Maximum Price Of Hk$40 Mln

Reuters
·
Sep 01

Antengene Board Approves HK$40 Million Share Buyback; Shares Jump 7%

MT Newswires Live
·
Sep 01

ANTENGENE-B (06996) Plans to Repurchase Shares Worth Up to HK$40 Million

Stock News
·
Sep 01

Antengene Corporation Ltd. Announces Intention for Share Repurchase Up to HK$40 Million

Reuters
·
Sep 01

Antengene Corp Ltd - to Repurchase Shares at Maximum Price of HK$40 Mln

THOMSON REUTERS
·
Sep 01

Hong Kong Stock Alert | ANTENGENE-B (06996) Surges Nearly 14% in Early Trading as ATG-022 Competitiveness Expected to Strengthen, Institutions Raise Mid-to-Long Term and Peak Sales Forecasts

Stock News
·
Aug 29

Stock Track | Antengene Soars 13.82% Amid Broader Biotech Rally in Hong Kong

Stock Track
·
Aug 29

HK Movers | Biotech Stocks Surge With Cutia Therapeutics up 14%

Tiger Newspress
·
Aug 29

Antengene Announces 2025 Interim Results With Encouraging Clinical Data and Progress in Tce Platform

THOMSON REUTERS
·
Aug 25

Antengene Narrows Loss in H1

MT Newswires Live
·
Aug 22

ANTENGENE-B (06996) Reports Interim Results with Adjusted Loss of RMB 72.858 Million, Down 52.25% YoY

Stock News
·
Aug 22

Antengene Corporation H1 Revenue RMB 53.2 Million

THOMSON REUTERS
·
Aug 22

Antengene's Cancer Therapy ATG-022 Granted Breakthrough Therapy Designation in China

MT Newswires Live
·
Aug 19

Antengene's Atg-022 (Cldn18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma

THOMSON REUTERS
·
Aug 19

Antengene - Atg-022 Granted Breakthrough Therapy Designation for Gastric Cancer by Center for Drug Evaluation (Cde) of China Nmpa

THOMSON REUTERS
·
Aug 19

ANTENGENE-B (06996) Shareholders Deposit Shares into Standard Chartered Bank (Hong Kong) with Market Value of HK$416 Million

Stock News
·
Aug 19

BUZZ-HK-listed Antengene at 2-1/2-year peak on Xpovio approval in China

Reuters
·
Jul 29

Antengene Gets China Nod for New Indication of Multiple Myeloma Drug

MT Newswires Live
·
Jul 28

Antengene Corporation Ltd. Secures Regulatory Approval for XPOVIO® in China for Second-Line Treatment of Multiple Myeloma

Reuters
·
Jul 28